---
figid: PMC3248310__JCI61453.f1
figlink: /pmc/articles/PMC3248310/figure/F1/
number: F1
caption: 'AA is a polyunsaturated fatty acid that constitutes the phospholipid domain
  of most cell membranes. It is liberated from cellular membranes by cPLA2. Free AA
  can be metabolized through three major pathways: the PTGS/COX pathway, the LOX pathway,
  and the CYP pathway. In the CYP pathway, AA is converted to EETs and HETEs by CYP
  epoxygenases and CYP ω-hydroxylases, respectively. The EETs are then further metabolized
  to less active DHETs by sEH. MSPPOH is a selective inhibitor of CYP epoxygenases,
  and HET0016 is a selective inhibitor of CYP ω-hydroxylases. AR9281 is a selective
  inhibitor of sEH and is currently under evaluation in phase II clinical trials as
  a treatment for patients with hypertension and type 2 diabetes.'
pmcid: PMC3248310
papertitle: 'Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases
  and cancer.'
reftext: Dingzhi Wang, et al. J Clin Invest. 2012 Jan 3;122(1):19-22.
pmc_ranked_result_index: '100009'
pathway_score: 0.8883359
filename: JCI61453.f1.jpg
figtitle: 'Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases
  and cancer'
year: '2012'
organisms: Homo sapiens
ndex: 5eb76772-df10-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3248310__JCI61453.f1.html
  '@type': Dataset
  description: 'AA is a polyunsaturated fatty acid that constitutes the phospholipid
    domain of most cell membranes. It is liberated from cellular membranes by cPLA2.
    Free AA can be metabolized through three major pathways: the PTGS/COX pathway,
    the LOX pathway, and the CYP pathway. In the CYP pathway, AA is converted to EETs
    and HETEs by CYP epoxygenases and CYP ω-hydroxylases, respectively. The EETs are
    then further metabolized to less active DHETs by sEH. MSPPOH is a selective inhibitor
    of CYP epoxygenases, and HET0016 is a selective inhibitor of CYP ω-hydroxylases.
    AR9281 is a selective inhibitor of sEH and is currently under evaluation in phase
    II clinical trials as a treatment for patients with hypertension and type 2 diabetes.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - COX5B
  - COX5A
  - COX6B2
  - CYP2C18
  - COX11
  - COX15
  - COX7A1
  - COX17
  - KAT5
  - COX7A2
  - COX4I1
  - COX7B2
  - COX8C
  - COX10
  - COX7B
  - TES
  - CYP4F3
  - LOX
  - COX8A
  - COX4I2
  - COX6A1
  - COX6B1
  - COX6A2
  - 5,6-EET
  - 14,15-EET
  - Arachidonic acid
  - Leukotrienes
genes:
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX5B
  entrez: '1329'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX5A
  entrez: '9377'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6B2
  entrez: '125965'
- word: CYP2C
  symbol: CYP2C
  source: hgnc_alias_symbol
  hgnc_symbol: CYP2C18
  entrez: '1562'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX11
  entrez: '1353'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX15
  entrez: '1355'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7A1
  entrez: '1346'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX17
  entrez: '10063'
- word: CPLA2
  symbol: cPLA2
  source: hgnc_alias_symbol
  hgnc_symbol: KAT5
  entrez: '10524'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7A2
  entrez: '1347'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX4I1
  entrez: '1327'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7B2
  entrez: '170712'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX8C
  entrez: '341947'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX10
  entrez: '1352'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX7B
  entrez: '1349'
- word: НЕTES
  symbol: TES
  source: hgnc_symbol
  hgnc_symbol: TES
  entrez: '26136'
- word: CYP4F
  symbol: CYP4F
  source: hgnc_alias_symbol
  hgnc_symbol: CYP4F3
  entrez: '4051'
- word: LOX
  symbol: LOX
  source: hgnc_symbol
  hgnc_symbol: LOX
  entrez: '4015'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX8A
  entrez: '1351'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX4I2
  entrez: '84701'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6A1
  entrez: '1337'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6B1
  entrez: '1340'
- word: PTGS/COX
  symbol: COX
  source: bioentities_symbol
  hgnc_symbol: COX6A2
  entrez: '1339'
chemicals:
- word: 5,6-EET
  source: MESH
  identifier: C040776
- word: 14,15-EET
  source: MESH
  identifier: C046782
- word: Arachidonic acid
  source: MESH
  identifier: D001095
- word: Leukotrienes
  source: MESH
  identifier: D015289
diseases: []
figid_alias: PMC3248310__F1
redirect_from: /figures/PMC3248310__F1
figtype: Figure
---
